Get the Stockscreener App
4.535
23.20%
-1.305
Nuvation Bio Inc stock is traded at $4.535, with a volume of 10.92M.
It is down -23.20% in the last 24 hours and down -23.98% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$5.84
Open:
$4.81
24h Volume:
10.92M
Relative Volume:
1.90
Market Cap:
$1.55B
Revenue:
$26.75M
Net Income/Loss:
$-217.48M
P/E Ratio:
-7.0837
EPS:
-0.6402
Net Cash Flow:
$-198.25M
1W Performance:
-20.48%
1M Performance:
-23.98%
6M Performance:
+42.38%
1Y Performance:
+146.43%
1-Day Range:
$4.24
$4.82
1-Week Range:
$4.24
$5.92
52-Week Range:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.535 | 2.00B | 26.75M | -217.48M | -198.25M | -0.6402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.81 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.54 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
753.52 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.21 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Royal Bank Of Canada Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
UBS Adjusts Price Target on Nuvation Bio to $7 From $10, Maintains Neutral Rating - marketscreener.com
Nuvation Bio price target raised to $13 from $12 at RBC Capital - TipRanks
RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch By Investing.com - Investing.com Canada
Nuvation Bio Posts Narrower FY25 Loss, Highlights IBTROZI Launch And Pipeline Progress; Stock Down - Nasdaq
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch - Investing.com
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
Nuvation Bio Q4 Earnings Call Highlights - Yahoo Finance
Nuvation Bio reports Q4 EPS (11c), consensus (5c) - TipRanks
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips - Investing.com
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Nuvation Bio Stock Is Dropping Despite Analyst Hikes - TipRanks
Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
Nuvation Bio Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:NUVB) 2026-03-02 - Seeking Alpha
Nuvation Bio (NUVB) launches IBTROZI and advances safusidenib, global partnerships - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Nuvation Bio Q4 Loss Narrows, Revenue Rises - marketscreener.com
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
NUVB: Rapid IBTROZI uptake, Eisai partnership, and improved net loss highlight Q4 2025 results - TradingView
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q4 Revenue $41.9M, vs. FactSet Est of $37.8M - marketscreener.com
Earnings Breakdown: Nuvation Bio Q4 - Benzinga
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - PR Newswire
Nuvation Bio earnings in focus: Ibtrozi momentum faces test - Investing.com
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Yahoo Finance
Nuvation Bio Expands SIGMA Study to Phase 3 Trial - Intellectia AI
11 Best Cancer Stocks to Invest In Now - Insider Monkey
A Look At Nuvation Bio’s Valuation As Safusidenib SIGMA Trial Advances To Phase 3 - Sahm
An Overview of Nuvation Bio's Earnings - Benzinga
Nuvation Bio Inc (NUVB) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Nuvation Bio Inc. (NUVB) Stock Analysis: A Biotech Gem With 104.98% Upside Potential - DirectorsTalk Interviews
Where is Nuvation Bio Inc. (NUVB) Headed According to Wall Street Analysts? - Finviz
10 Small-Cap Stocks With Huge Growth Potential - Insider Monkey
Nuvation Bio to Participate in Upcoming Investor Conferences - The Malaysian Reserve
Nuvation Bio to Participate in Upcoming March 2026 Investor Conferences - BioSpace
Cancer-focused Nuvation Bio lines up four March investor events - Stock Titan
Published on: 2026-02-25 12:26:14 - baoquankhu1.vn
Nuvation Bio drives lung cancer therapy innovation at TTLC 2026 - Traders Union
Nuvation Bio (NUVB) Expected to Announce Earnings on Monday - MarketBeat
Is It Time To Revisit Nuvation As IBTROZI Gains Traction? - RTTNews
Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) - Seeking Alpha
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 - BioSpace
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financi - GuruFocus
Nuvation Bio to host 2025 earnings call amid business update - Traders Union
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - Benzinga
Guidance Update: Will Nuvation Bio Inc outperform the market in YEARQuarterly Performance Summary & Weekly Momentum Stock Picks - baoquankhu1.vn
GSA Capital Partners LLP Decreases Position in Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Nuvation Bio Inc. (NUVB) Stock Analysis: Unveiling a 105% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Nuvation Bio Inc. (NYSE:NUVB) Is Expected To Breakeven In The Near Future - 富途牛牛
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):